echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > One hand evaluation, one hand guarantee payment: heavy innovative drugs are becoming truly accessible

    One hand evaluation, one hand guarantee payment: heavy innovative drugs are becoming truly accessible

    • Last Update: 2019-11-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Original: 1 ° C On November 28, 2019, the 2019 medical insurance negotiation directory arrived as scheduled! During the negotiation process of AstraZeneca oral hypoglycemic drug digrinin, we swipe the screen of friends, 5.62 yuan - 4.72 yuan - 4.62 yuan - 4.50 yuan - 4.40 yuan - 4.36 yuan We can see that "price reduction" is still the key to the success of 2019 medical insurance negotiation Since 2017, the State Drug Administration has vigorously implemented the reform and issued a number of landmark policies that have a profound impact on the development direction of the industry, such as consistency evaluation, priority review, clinical urgent need for overseas new drugs, rare catalogue, establishment of the health insurance bureau, medical insurance negotiation, centralized procurement, etc on the one hand, the state is opening up a new rapid review for the real clinical urgent need for heavy innovative drugs On the other hand, the state actively improves patients' ability to pay Think of a famous Golden sentence - "this is the best era, this is the worst era." This paper focuses on the 2019 medical insurance negotiation catalogue, autoimmunity, AIDS, hepatitis C and rare diseases According to CCTV news, in this negotiation, experts reviewed and voted to propose 128 negotiation drug alternative lists After the enterprises confirmed the negotiation intention, 119 drugs were determined as new negotiation varieties In addition, 31 of the varieties that were negotiated for access in 2017 need to be negotiated again to determine whether to renew the contract In recent years, most of the drugs that have been successfully negotiated are new drugs with high clinical value, involving more than 10 clinical treatment fields such as cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc In terms of key areas, all five essential drugs were successfully negotiated, 22 anticancer drugs, 7 drugs for rare diseases, 14 drugs for chronic diseases (including diabetes, hepatitis B, rheumatoid arthritis, etc.) and 4 drugs for children were successfully negotiated Among the varieties successfully negotiated, 70 were added and 27 were "renewed" The price of 70 new drugs decreased by 60.7% on average, and that of 27 renewed drugs decreased by 26.4% on average The patients' personal burden is reduced by more than 80% and the individual drug burden is reduced by more than 95% Note: in 2017, there were 36 varieties in the medical insurance negotiation catalogue, of which 5 (tegrilol, abitrone, rituximab, bortezomib, lenalidomide) were not listed in the 2019 negotiation catalogue due to the approval of generic drugs, and 4 (fluvectin, recombinant human interferon beta-1b, tofapurtan, lapatinib) failed in the negotiation Topiramab: 1925.00 yuan / dose, adjusted to 830.00 yuan / dose, - 57%, 60kg body weight, about 60000 / year Xiumeile: 7608.38 yuan / piece is adjusted to 3160 yuan / piece, - 58%, medical insurance negotiation is further - 59%, 33 thousand / year; Enli: 2400 yuan / piece is adjusted to 699 yuan / piece, - 70%, 73000 yuan / year; Market pattern of drugs for autoimmune diseases in China (percentage represents sales market share) Data source: Sansheng pharmaceutical After the health insurance negotiation in 2019, eight macromolecular drugs of rheumatoid, psoriasis, ulcerative colitis and Crohn's disease have been included in the health insurance China's autoimmune market will change! It is a cruel fact that the drug accessibility of AIDS patients in China is far less than that of African countries The inclusion of Gilead's HIV drug, ceftriaxone propionate (E / C / F / TAF), in the 2019 healthcare negotiation catalogue is a commendable beginning AIDS patients finally ushered in a single tablet (STR) complete program I hope biktarvy will be the next anti AIDS drug to enter the medical insurance! From the analysis of the author's previous articles, we can know that TAF is the integrated enzyme inhibitor program with the basic composition, single tablet, which has become the mainstream program of global AIDS treatment In 2018 and 2019, genvoya and biktarvy have been listed in China successively, and genvoya is included in the medical insurance this time, which greatly reduces the drug burden of AIDS in China, and significantly improves the innovative drugs Accessibility In the long run, biktarvy is the smallest single triple compound preparation based on integrated enzyme chain transfer inhibitors, which has good safety and effectiveness and will be the king of the future market; In the long run, the market share of the (long-term) 2DR program represented by Juluca will increase year by year after the chronic AIDS Improving compliance and reducing drug exposure at the same time will be a trend worthy of attention in the future, calling for the attention of the state!!! With the approval of DAAS in China, China will enter a new era of complete oral treatment of DAAS, Following Europe and the United States closely and opening the era of hepatitis C cure, at present, 9 DAAS schemes have been approved in China, while 3 DAAS are in the stage of market review, and it is expected that all of them will be approved for listing in 2019-2020 Similarly, it can be seen that the import scheme of entering the medical insurance is better than that of Geli pharmaceutical Up to now, various enterprises have published price display: 1 The price of imported drugs is between 58000-60000 / 12 weeks; 2 The price of domestic drugs is about 40000 yuan / 12 weeks; Zepatier, epclusa and harvoni will greatly improve the health status of hepatitis C patients in China Looking forward to maviret's next round of medical insurance!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.